GLP-1 medications, explained without the hype
What the STEP and SURMOUNT clinical trials actually showed, who qualifies, and the side effects nobody puts in ads.
In medical review. Publishing soon.
The library
Read before you decide anything.
Every article here is written to one standard: lead with the evidence, name the risks, cite the sources. Each will carry the name and license of the physician who reviewed it.
Now published
Microdosing GLP-1s: a straight answer
Low-dose GLP-1 programs are suddenly everywhere. What the term actually means, what the evidence supports, and the questions to ask before you pay anyone.
Read the article →Compounded medications: what the rules actually say
FDA-approved versus compounded is not a small distinction. What changed in 2025 and 2026, in plain English.
In medical review. Publishing soon.
Peptide therapies: where FDA rulemaking stands in 2026
Six peptides took a step toward legal compounding in July 2026. What that does, and does not, mean for patients.
In medical review. Publishing soon.
Want these when they publish?
The waitlist gets every article first. Join here.